Compare BRID & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | ANVS |
|---|---|---|
| Founded | 1932 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 46.5M |
| IPO Year | 1995 | 2019 |
| Metric | BRID | ANVS |
|---|---|---|
| Price | $7.58 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 3.2K | ★ 1.1M |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $7.00 | $1.36 |
| 52 Week High | $8.73 | $5.50 |
| Indicator | BRID | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 37.87 |
| Support Level | $7.36 | $1.57 |
| Resistance Level | $8.06 | $2.99 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 13.02 | 19.47 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.